Core Insights - Acadia Healthcare is a leading provider in the behavioral healthcare sector, offering a range of services including psychiatric and addiction treatment [1] - The company is facing challenges related to governance and performance, as highlighted by a major shareholder's call for a strategic review [3] Stock Performance - On October 3, 2025, Raymond James upgraded Acadia Healthcare to "Outperform" with a new price target of $30, up from $26, indicating a positive outlook for the stock [2][5] - ACHC's stock price increased by 8.43%, or $2.07, reflecting strong investor interest, with a trading range of $24.57 to $26.72 for the day [4][5] - Over the past year, ACHC has experienced significant volatility, with a high of $60.52 and a low of $17.13 [4] Market Position - Acadia Healthcare's market capitalization is approximately $2.46 billion, indicating its substantial presence in the market [4] - The trading volume for ACHC today was 3,511,931 shares on the NASDAQ exchange, demonstrating active investor engagement [4]

My top 10 things to watch Friday, Oct. 3 1. Boeing problems: The planemaker's new 777X widebody jet is now set to make its commercial debut in early 2027 instead of next year, Bloomberg reported this morning. That delay could expose Club name Boeing to sizable non-cash accounting charges. Safety certification work is taking longer than expected. 2. BlackRock's Global Infrastructure Partners is seemingly negotiating to buy everything. This time, GIP is in talks to buy Aligned Data Centers in a transaction va ...

Core Viewpoint - Ferrari has received a stock rating upgrade from HSBC, indicating positive investor sentiment and potential for growth in the luxury automotive market [1][5]. Company Overview - Ferrari is a luxury sports car manufacturer listed on the NYSE under the symbol RACE, competing with brands like Lamborghini and Porsche [1]. - The company's market capitalization is approximately $87.37 billion, highlighting its significant presence in the luxury automotive industry [4][5]. Stock Performance - The stock price of Ferrari is currently $490.24, reflecting an increase of 1.03%, or $5.02, following the upgrade [2][5]. - The stock has shown a price movement of 0.91%, suggesting strong market performance [2][5]. - Ferrari's stock has fluctuated between a low of $481.75 and a high of $490.95 on the current trading day, with a yearly range of $391.54 to $519.10, indicating volatility and growth potential [3]. Investor Engagement - The trading volume for Ferrari's stock today is 375,078 shares, indicating active investor interest and engagement [4].

ANALYSIS: The Market Threat From A Federal Shutdown Take a Trial Today Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! IBD Videos Celsius stock traded in a buy zone Tuesday after receiving an upgrade from Morgan Stanley. Shares of the energy drink maker made an actionable rebound earlier this week. Morgan Stanley on Tuesday upgraded Celsius (CELH) to overweight from equal weight, citing its accelerating growth, according to Th ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Goldman Sachs upgraded Innoviz Technologies (INVZ) to Buy from Neutral with a price target of $2.50, up from $1.50. The firm cites the company's design potential over the next six months and its "inexpensive" valuation for the upgrade.Morgan Stanley upgraded Citizens Financial (CFG) to Overweight from Equal Weight ...

Group 1 - Wells Fargo upgraded Adient from Equal Weight to Overweight, raising its price target to $31 from $24, with shares rising nearly 2% in pre-market trading [1] - Adient is expected to benefit from improved global light vehicle production in 2026, with adjusted EBITDA projected to be about 7% above consensus [1] - The stock is currently trading at near-trough valuation multiples, indicating potential for growth [1] Group 2 - The company's turnaround has faced delays due to weak global production, unfavorable customer mix, extended unprofitable programs, and persistent cost inflation [2] - Margin recovery is anticipated to accelerate starting in 2026 as North American volumes improve, foreign exchange trends stabilize, and unprofitable programs are phased out [2]

Core Viewpoint - UBS upgraded its rating on General Motors (GM) from neutral to buy and increased its price target from $56 to $81, indicating a positive outlook for the company's stock performance [1] Group 1 - UBS's upgrade led to a stock gain of over 2% for General Motors following the announcement [1]

Core Viewpoint - Union Pacific Corp. received an upgrade from Citi analyst Ariel Rosa, moving from neutral to buy, due to attractive valuation and improved operational metrics [1] Summary by Relevant Categories Company Analysis - The upgrade reflects Wall Street's confidence in Union Pacific Corp.'s financial health and market position [1] - The analyst highlighted the company's attractive valuation as a key factor for the upgrade [1] Market Reaction - The upgrade is expected to positively influence investor sentiment towards Union Pacific Corp. [1] - Improved operational metrics were cited as a reason for the upgrade, indicating potential for future growth [1]

Alaska Air Group Inc (NYSE:ALK) stock is up 1.8% to trade at $65.04, after UBS upgraded the Washington-based airliner to "buy" from "neutral" with a price-target hike to $90 from $56, citing the company's initiatives moving forward. J.P. Morgan Securities also chimed in with a price-target hike to $96 from $73. These bull notes come a couple days after Alaska Air announced that Diana Birkett Rakow, Senior V.P. of public affairs and sustainability at Alaska Airlines, will become CEO of Hawaiian Airlines, whi ...

Group 1 - Gossamer Bio's shares increased after UBS upgraded the stock from Neutral to Buy, indicating a positive outlook for the company [2] - The upgrade is based on an "underappreciated" late-stage data catalyst related to Gossamer Bio's lead asset, seralutinib [2] - This upgrade comes at a strategic time for the company, suggesting potential for growth and investor interest [2]